Sagimet Biosciences Inc (SGMT) PT Lowered to $12 at Citizens on Acne Pivot May 19, 2026 04:10AM
Sagimet Biosciences Inc (SGMT) PT Raised to $33 at Oppenheimer Apr 30, 2026 05:26PM
Sagimet Biosciences Inc (SGMT) PT Raised to $28 at Oppenheimer Apr 27, 2026 11:29AM
Sagimet prices $175 million stock offering at $6 per share Apr 27, 2026 07:15AM
Sagimet Biosciences plans Phase 3 acne trial for second half of 2026 Apr 27, 2026 07:01AM


Mar 12, 2026 05:30AM Sagimet Biosciences (SGMT) Reiterated at Market Outperform by Citizens
Mar 11, 2026 04:04PM Oppenheimer Reiterates Outperform Rating on Sagimet Biosciences Inc (SGMT) following Q4 results
Feb 3, 2026 06:12AM Guggenheim Starts Sagimet Biosciences Inc (SGMT) at Buy
Dec 10, 2025 07:04AM Sagimet partner gets China approval to file acne drug application
Nov 14, 2025 06:16AM Sagimet Biosciences (SGMT) PT Raised to $35 at Citizens After MASH Drug Presentations
Oct 21, 2025 04:21PM Clear Street Starts Sagimet Biosciences Inc (SGMT) at Buy, PT $29
Aug 13, 2025 08:34AM Sagimet Biosciences Inc. (SGMT) Tops Q2 EPS by 56c
Aug 11, 2025 06:52AM Wedbush Starts Sagimet Biosciences Inc (SGMT) at Outperform
Aug 7, 2025 06:07AM H.C. Wainwright Assumes Sagimet Biosciences Inc (SGMT) at Buy
Jun 17, 2025 04:10AM Citizens JMP Reiterates Market Outperform Rating on Sagimet Biosciences Inc (SGMT)
Jun 4, 2025 06:25AM Leerink Partners Reiterates Outperform Rating on Sagimet Biosciences Inc (SGMT)
Jun 4, 2025 05:56AM Sagimet Biosciences (SGMT) Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
Mar 12, 2025 04:04PM Sagimet Biosciences Inc. (SGMT) Misses Q4 EPS by 1c
Dec 5, 2024 04:09PM Oppenheimer Starts Sagimet Biosciences Inc (SGMT) at Outperform
Nov 18, 2024 07:33AM H.C. Wainwright Reiterates Buy Rating on Sagimet Biosciences Inc (SGMT)
Nov 12, 2024 03:21AM UBS Starts Sagimet Biosciences Inc (SGMT) at Buy
Oct 11, 2024 07:00AM Sagimet Biosciences (SGMT) Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH
Oct 4, 2024 05:54AM Leerink Partners Reiterates Outperform Rating on Sagimet Biosciences Inc (SGMT)
Oct 1, 2024 10:24AM Leerink Partners Reiterates Outperform Rating on Sagimet Biosciences Inc (SGMT)
Aug 20, 2024 08:14AM TD Cowen Reiterates Buy Rating on Sagimet Biosciences Inc (SGMT)
Aug 15, 2024 04:53PM Sagimet Biosciences Inc. (SGMT) Tops Q2 EPS by 25c
Jun 28, 2024 03:29AM Goldman Sachs Downgrades Sagimet Biosciences Inc (SGMT) to Neutral
Jun 10, 2024 10:25AM TD Cowen Reiterates Buy Rating on Sagimet Biosciences Inc (SGMT)